New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 2, 2013
16:36 EDTMYGNMyriad Genetics sees FY13 EPS at high end of previous range $1.55 -$1.58
Consensus for FY13 EPS is $1.57. Myriad Genetics sees FY13 revenue to be at the high end of the previous range $575M-$585M. Consensus for FY13 revenue is $583.30M.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
09:21 EDTMYGNIridian Asset reports 5.5% passive stake in Myriad Genetics
08:31 EDTMYGNMyriad Genetics guidance at risk, says Morgan Stanley
Subscribe for More Information
January 26, 2015
07:17 EDTMYGNSociety of Thoracic Surgeons to hold annual meeting
51st Annual Meeting of STS is being held in San Diego, California on January 24-28.
January 23, 2015
15:46 EDTMYGNPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
January 20, 2015
07:07 EDTMYGNMyriad RBM joins Institut Pasteur in TB collaboration
Myriad RBM, a wholly owned subsidiary of Myriad Genetics, announced that it will assist the Institut Pasteur in a public-private research collaboration to fight the global tuberculosis, or TB, epidemic. This research project is funded by the Bill & Melinda Gates Foundation through a grant to the Institut Pasteur. The proof-of-concept study will evaluate patients with latent and active TB infections who are affiliated with the South African Tuberculosis Vaccine Initiative clinical study sites. The goals of this study are to field-test Myriad RBM's TruCulture system as a point-of-care blood collection and immune response monitoring method and to stratify patients with active and latent tuberculosis.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use